Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial

Shinkai et al., Infectious Diseases and Therapy, doi:10.1007/s40121-021-00517-4
Aug 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Time to improvement 37% Improvement Relative Risk Time to improvement (b) 59% Favipiravir  Shinkai et al.  LATE TREATMENT  RCT Is late treatment with favipiravir beneficial for COVID-19? RCT 156 patients in Japan Faster recovery with favipiravir (p=0.014) c19early.org Shinkai et al., Infectious Diseases an.., Aug 2021 Favorsfavipiravir Favorscontrol 0 0.5 1 1.5 2+
RCT 156 patients in Japan, 107 treated with favipiravir, showing significant improvement in a composite outcome defined as the time to improvement in temperature, SpO2, CT findings, and recovery to PCR-.
time to improvement, 37.1% lower, HR 0.63, p = 0.01, treatment 107, control 49, adjusted per study, inverted to make HR<1 favor treatment, Cox proportional hazards, composite time to improvement in temperature, SpO2, CT findings, and recovery to PCR-.
time to improvement, 58.5% lower, HR 0.41, p = 0.01, treatment 47, control 13, adjusted per study, inverted to make HR<1 favor treatment, <5 days from onset of fever, Cox proportional hazards, composite time to improvement in temperature, SpO2, CT findings, and recovery to PCR-.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shinkai et al., 27 Aug 2021, Single Blind Randomized Controlled Trial, Japan, peer-reviewed, 39 authors, average treatment delay 4.8 days.
This PaperFavipiravirAll
Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial
Masaharu Shinkai, Kenji Tsushima, Shingo Tanaka, Eri Hagiwara, Norihito Tarumoto, Ichiro Kawada, Yuji Hirai, Sho Fujiwara, Yuko Komase, Takeshi Saraya, Hidefumi Koh, Naho Kagiyama, Megumi Shimada, Daiki Kanou, Shinichi Antoku, Yujiro Uchida, Yutaka Tokue, Mikio Takamori, Yasuhiro Gon, Kenya Ie, Yoshitaka Yamazaki, Kazumasa Harada, Naoki Miyao, Takashi Naka, Mitsunaga Iwata, Atsushi Nakagawa, Kazutoshi Hiyama, Yoshihiko Ogawa, Masahiro Shinoda, Shinichiro Ota, Takatomo Hirouchi, Jiro Terada, Shuichi Kawano, Takashi Ogura, Tsutomu Sakurai, Yoshihiko Matsumoto, Hiroyuki Kunishima, Osamu Kobayashi, Satoshi Iwata
Infectious Diseases and Therapy, doi:10.1007/s40121-021-00517-4
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 , is an enveloped, single-stranded RNA virus. Favipi-ravir is an orally administrable antiviral drug whose mechanism of action is to selectively inhibit RNA-dependent RNA polymerase. A preliminary trial in COVID-19 patients reported significant improvements across a multitude of clinical parameters, but these findings have not been confirmed in an adequate well-controlled trial. We conducted a randomized, single-blind, placebo-controlled Phase III trial assessing the efficacy and safety of favipiravir in patients with Supplementary Information The online version contains supplementary material available at https://
Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Authorship Contributions. Conceptualization: Satoshi Iwata, Tsutomu Sakurai; Methodology: Satoshi Iwata, Osamu Kobayashi, Hiroyuki Kunishima, Masaharu Shinkai; Formal analysis: Yoshihiko Matsumoto, Tsutomu Sakurai; Investigation: Masaharu Shinkai, Kenji Tsushima, Shingo Tanaka, Eri Hagiwara, Norihito Tarumoto, Ichiro Kawada, Yuji Hirai, Sho Fujiwara, Yuko Komase, Takeshi Saraya, Hidefumi Koh, Naho Kagiyama, Megumi Shimada, Daiki Kanou, Shinichi Antoku, Yujiro Uchida, Yutaka Tokue, Mikio Takamori, Yasuhiro Gon, Kenya Ie, Yoshitaka Yamazaki, Kazumasa Harada, Naoki Miyao, Takashi Naka, Mitsunaga Iwata, Atsushi Nakagawa, Kazutoshi Hiyama, Yoshihiko Ogawa, Masahiro Shinoda, Shinichiro Ota, Takatomo Hirouchi, Jiro Terada, Shuichi Kawano and Takashi Ogura; Supervision: Satoshi Iwata; Writing -original draft preparation; Masaharu Shinkai. All authors commented on previous versions of the manuscript. All authors read and approved the submitted version. Disclosures. Tsutomu Sakurai and Yoshihiko Matsumoto are employees of the sponsor. Masaharu Shinkai, Kenji Tsushima, Shingo Tanaka, Eri Hagiwara, Norihito Tarumoto, Ichiro Kawada, Yuji Hirai, Sho Fujiwara, Yuko Komase, Takeshi Saraya, Hidefumi Koh, Naho Kagiyama, Megumi..
References
Cai, Yang, Liu, Experimental treatment with favipiravir for COVID-19: An open-label control study, Eng
Cele, Gazy, Jackson, Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma, Nature
Cui, Hung, Wang, Modification of sample size in group sequential clinical trials, Biometrics
Doi, Hibino, Hase, A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19, Antimicrob Agents Chemother
Fujii, Ibe, Ishigo, Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients, J Infect Chemother
Galloway, Paul, Maccannell, Emergence of SARS-CoV-2 B.1.1.7 Lineage-United States, MMWR Morb Mortal Wkly Rep
Gordon, Tchesnokov, Woolner, Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency, J Biol Chem
Gowen, Wong, Jung, In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections, Antimicrob Agents Chemother
Ivashchenko, Dmitriev, Vostokova, AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial, Clin Infect Dis
Kaptein, Jacobs, Langendries, Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity, Proc Natl Acad Sci
Li, Wu, Nie, The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity, Cell
Mendenhall, Russell, Smee, Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever, PLoS Negl Trop Dis
Morikawa, Shinoda, Ota, Clinical features of 154 COVID-19 patients and parameters for effective detection of pneumonia at the time of initial diagnosis in Japan, Intern Med
Oxley, Mocco, Majidi, Large-vessel stroke as a presenting feature of Covid-19 in the young, N Engl J Med
Shanon, Selisko, Le, Rapid incorporation of favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis, Nat Commun
Sidwell, Barnard, Day, Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice, Antimicrob Agents Chemother
Suemori, Saijo, Yamanaka, A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome, PLoS Negl Trop Dis
Udwadia, Singh, Barkate, Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial, Int J Infect Dis
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Chen, Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment, Eur J Pharmacol
Wo ¨lfel, Corman, Guggemos, Virological assessment of hospitalized patients with COVID-2019, Nature
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
{ 'indexed': {'date-parts': [[2024, 3, 28]], 'date-time': '2024-03-28T10:36:05Z', 'timestamp': 1711622165879}, 'reference-count': 24, 'publisher': 'Springer Science and Business Media LLC', 'issue': '4', 'license': [ { 'start': { 'date-parts': [[2021, 8, 27]], 'date-time': '2021-08-27T00:00:00Z', 'timestamp': 1630022400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}, { 'start': { 'date-parts': [[2021, 8, 27]], 'date-time': '2021-08-27T00:00:00Z', 'timestamp': 1630022400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}], 'funder': [ { 'DOI': '10.13039/501100019949', 'name': 'FUJIFILM Toyama Chemical CO', 'doi-asserted-by': 'crossref'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021, 12]]}, 'DOI': '10.1007/s40121-021-00517-4', 'type': 'journal-article', 'created': {'date-parts': [[2021, 8, 27]], 'date-time': '2021-08-27T18:02:36Z', 'timestamp': 1630087356000}, 'page': '2489-2509', 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 49, 'title': 'Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen ' 'Therapy: A Randomized, Phase III Clinical Trial', 'prefix': '10.1007', 'volume': '10', 'author': [ {'given': 'Masaharu', 'family': 'Shinkai', 'sequence': 'first', 'affiliation': []}, {'given': 'Kenji', 'family': 'Tsushima', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shingo', 'family': 'Tanaka', 'sequence': 'additional', 'affiliation': []}, {'given': 'Eri', 'family': 'Hagiwara', 'sequence': 'additional', 'affiliation': []}, {'given': 'Norihito', 'family': 'Tarumoto', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ichiro', 'family': 'Kawada', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yuji', 'family': 'Hirai', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sho', 'family': 'Fujiwara', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yuko', 'family': 'Komase', 'sequence': 'additional', 'affiliation': []}, {'given': 'Takeshi', 'family': 'Saraya', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hidefumi', 'family': 'Koh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Naho', 'family': 'Kagiyama', 'sequence': 'additional', 'affiliation': []}, {'given': 'Megumi', 'family': 'Shimada', 'sequence': 'additional', 'affiliation': []}, {'given': 'Daiki', 'family': 'Kanou', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shinichi', 'family': 'Antoku', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yujiro', 'family': 'Uchida', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yutaka', 'family': 'Tokue', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mikio', 'family': 'Takamori', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yasuhiro', 'family': 'Gon', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kenya', 'family': 'Ie', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yoshitaka', 'family': 'Yamazaki', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kazumasa', 'family': 'Harada', 'sequence': 'additional', 'affiliation': []}, {'given': 'Naoki', 'family': 'Miyao', 'sequence': 'additional', 'affiliation': []}, {'given': 'Takashi', 'family': 'Naka', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mitsunaga', 'family': 'Iwata', 'sequence': 'additional', 'affiliation': []}, {'given': 'Atsushi', 'family': 'Nakagawa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kazutoshi', 'family': 'Hiyama', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yoshihiko', 'family': 'Ogawa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Masahiro', 'family': 'Shinoda', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shinichiro', 'family': 'Ota', 'sequence': 'additional', 'affiliation': []}, {'given': 'Takatomo', 'family': 'Hirouchi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jiro', 'family': 'Terada', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shuichi', 'family': 'Kawano', 'sequence': 'additional', 'affiliation': []}, {'given': 'Takashi', 'family': 'Ogura', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tsutomu', 'family': 'Sakurai', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yoshihiko', 'family': 'Matsumoto', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hiroyuki', 'family': 'Kunishima', 'sequence': 'additional', 'affiliation': []}, {'given': 'Osamu', 'family': 'Kobayashi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Satoshi', 'family': 'Iwata', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2021, 8, 27]]}, 'reference': [ { 'key': '517_CR1', 'unstructured': 'Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly ' 'Operational Upd. Geneva: World Health Organization. 2021. ' 'https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19---10-may-2021. ' 'Accessed 10 May 2021.'}, { 'key': '517_CR2', 'doi-asserted-by': 'publisher', 'first-page': '3168', 'DOI': '10.1128/AAC.00356-07', 'volume': '51', 'author': 'BB Gowen', 'year': '2007', 'unstructured': 'Gowen BB, Wong MH, Jung KH, et al. In vitro and in vivo activities of ' 'T-705 against arenavirus and bunyavirus infections. Antimicrob Agents ' 'Chemother. 2007;51:3168–76.', 'journal-title': 'Antimicrob Agents Chemother'}, { 'key': '517_CR3', 'doi-asserted-by': 'publisher', 'first-page': 'e1342', 'DOI': '10.1371/journal.pntd.0001342', 'volume': '5', 'author': 'M Mendenhall', 'year': '2011', 'unstructured': 'Mendenhall M, Russell A, Smee DF, et al. Effective oral favipiravir ' '(T-705) therapy initiated after the onset of clinical disease in a model ' 'of arenavirus hemorrhagic fever. PLoS Negl Trop Dis. 2011;5:e1342.', 'journal-title': 'PLoS Negl Trop Dis'}, { 'key': '517_CR4', 'doi-asserted-by': 'publisher', 'first-page': '269', 'DOI': '10.1038/s41422-020-0282-0', 'volume': '30', 'author': 'M Wang', 'year': '2020', 'unstructured': 'Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively ' 'inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. ' 'Cell Res. 2020;30:269–71.', 'journal-title': 'Cell Res'}, { 'key': '517_CR5', 'doi-asserted-by': 'publisher', 'first-page': '4682', 'DOI': '10.1038/s41467-020-18463-z', 'volume': '11', 'author': 'A Shanon', 'year': '2020', 'unstructured': 'Shanon A, Selisko B, Le NT, et al. Rapid incorporation of favipiravir by ' 'the fast and permissive viral RNA polymerase complex results in ' 'SARS-CoV-2 lethal mutagenesis. Nat Commun. 2020;11:4682.', 'journal-title': 'Nat Commun'}, { 'key': '517_CR6', 'doi-asserted-by': 'publisher', 'first-page': '6785', 'DOI': '10.1074/jbc.RA120.013679', 'volume': '295', 'author': 'CJ Gordon', 'year': '2020', 'unstructured': 'Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a ' 'direct-acting antiviral that inhibits RNA-dependent RNA polymerase from ' 'severe acute respiratory syndrome coronavirus 2 with high potency. J ' 'Biol Chem. 2020;295:6785–97.', 'journal-title': 'J Biol Chem'}, { 'key': '517_CR7', 'first-page': '1192', 'volume': '6', 'author': 'Q Cai', 'year': '2020', 'unstructured': 'Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for ' 'COVID-19: An open-label control study. Eng (Beijing). 2020;6:1192–8.', 'journal-title': 'Eng (Beijing)'}, { 'key': '517_CR8', 'unstructured': 'Favipiravir Observational Study Group, Fujita Health University. Interim ' 'report of the Favipiravir Observational Study in Japan. 2020. ' 'https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_favip_210419_eng.pdf.'}, { 'key': '517_CR9', 'doi-asserted-by': 'publisher', 'first-page': '845', 'DOI': '10.1128/AAC.01051-06', 'volume': '51', 'author': 'RW Sidwell', 'year': '2007', 'unstructured': 'Sidwell RW, Barnard DL, Day CW, et al. Efficacy of orally administered ' 'T-705 on lethal avian influenza A (H5N1) virus infections in mice. ' 'Antimicrob Agents Chemother. 2007;51:845–51.', 'journal-title': 'Antimicrob Agents Chemother'}, { 'key': '517_CR10', 'doi-asserted-by': 'publisher', 'first-page': 'e0009103', 'DOI': '10.1371/journal.pntd.0009103', 'volume': '22', 'author': 'K Suemori', 'year': '2021', 'unstructured': 'Suemori K, Saijo M, Yamanaka A, et al. A multicenter non-randomized, ' 'uncontrolled single arm trial for evaluation of the efficacy and the ' 'safety of the treatment with favipiravir for patients with severe fever ' 'with thrombocytopenia syndrome. PLoS Negl Trop Dis. 2021;22:e0009103.', 'journal-title': 'PLoS Negl Trop Dis'}, { 'key': '517_CR11', 'doi-asserted-by': 'publisher', 'first-page': '853', 'DOI': '10.1111/j.0006-341X.1999.00853.x', 'volume': '55', 'author': 'L Cui', 'year': '1999', 'unstructured': 'Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential ' 'clinical trials. Biometrics. 1999;55:853–7.', 'journal-title': 'Biometrics'}, { 'key': '517_CR12', 'doi-asserted-by': 'publisher', 'first-page': '31', 'DOI': '10.2169/internalmedicine.5528-20', 'volume': '60', 'author': 'M Morikawa', 'year': '2021', 'unstructured': 'Morikawa M, Shinoda M, Ota S, et al. Clinical features of 154 COVID-19 ' 'patients and parameters for effective detection of pneumonia at the time ' 'of initial diagnosis in Japan. Intern Med. 2021;60:31–7.', 'journal-title': 'Intern Med'}, { 'key': '517_CR13', 'doi-asserted-by': 'publisher', 'first-page': '62', 'DOI': '10.1016/j.ijid.2020.11.142', 'volume': '103', 'author': 'ZF Udwadia', 'year': '2021', 'unstructured': 'Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of ' 'favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in ' 'mild-to-moderate COVID-19: a randomized, comparative, open-label, ' 'multicenter, phase 3 clinical trial. Int J Infect Dis. 2021;103:62–71.', 'journal-title': 'Int J Infect Dis'}, { 'key': '517_CR14', 'first-page': 'ciaa1176', 'volume': '2020', 'author': 'AA Ivashchenko', 'year': '2020', 'unstructured': 'Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for treatment ' 'of patients with moderate COVID-19: interim results of a phase II/III ' 'multicenter randomized clinical trial. Clin Infect Dis. ' '2020;2020:ciaa1176.', 'journal-title': 'Clin Infect Dis'}, { 'key': '517_CR15', 'doi-asserted-by': 'publisher', 'first-page': 'e01897-20', 'DOI': '10.1128/AAC.01897-20', 'volume': '64', 'author': 'Y Doi', 'year': '2020', 'unstructured': 'Doi Y, Hibino M, Hase R, et al. A prospective, randomized, open-label ' 'trial of early versus late favipiravir therapy in hospitalized patients ' 'with COVID-19. Antimicrob Agents Chemother. 2020;64:e01897-20.', 'journal-title': 'Antimicrob Agents Chemother'}, { 'key': '517_CR16', 'doi-asserted-by': 'publisher', 'first-page': '26955', 'DOI': '10.1073/pnas.2014441117', 'volume': '117', 'author': 'SJF Kaptein', 'year': '2020', 'unstructured': 'Kaptein SJF, Jacobs S, Langendries L, et al. Favipiravir at high doses ' 'has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas ' 'hydroxychloroquine lacks activity. Proc Natl Acad Sci USA. ' '2020;117:26955–65.', 'journal-title': 'Proc Natl Acad Sci USA'}, { 'key': '517_CR17', 'doi-asserted-by': 'publisher', 'first-page': '173634', 'DOI': '10.1016/j.ejphar.2020.173634', 'volume': '889', 'author': 'Y Wang', 'year': '2020', 'unstructured': 'Wang Y, Chen L. Tissue distributions of antiviral drugs affect their ' 'capabilities of reducing viral loads in COVID-19 treatment. Eur J ' 'Pharmacol. 2020;889:173634.', 'journal-title': 'Eur J Pharmacol'}, { 'key': '517_CR18', 'doi-asserted-by': 'publisher', 'first-page': '1051', 'DOI': '10.1016/j.jiac.2021.04.013', 'volume': '27', 'author': 'S Fujii', 'year': '2021', 'unstructured': 'Fujii S, Ibe Y, Ishigo T, et al. Early favipiravir treatment was ' 'associated with early defervescence in non-severe COVID-19 patients. J ' 'Infect Chemother. 2021;27:1051–7.', 'journal-title': 'J Infect Chemother.'}, { 'key': '517_CR19', 'doi-asserted-by': 'publisher', 'first-page': '1054', 'DOI': '10.1016/S0140-6736(20)30566-3', 'volume': '395', 'author': 'F Zhou', 'year': '2020', 'unstructured': 'Zhou F, Yu T, Du R, et al. Clinical course and risk factors for ' 'mortality of adult inpatients with COVID-19 in Wuhan, China: a ' 'retrospective cohort study. Lancet. 2020;395:1054–62.', 'journal-title': 'Lancet'}, { 'key': '517_CR20', 'doi-asserted-by': 'publisher', 'first-page': 'e60', 'DOI': '10.1056/NEJMc2009787', 'volume': '382', 'author': 'TJ Oxley', 'year': '2020', 'unstructured': 'Oxley TJ, Mocco J, Majidi S, et al. Large-vessel stroke as a presenting ' 'feature of Covid-19 in the young. N Engl J Med. 2020;382:e60.', 'journal-title': 'N Engl J Med'}, { 'key': '517_CR21', 'doi-asserted-by': 'publisher', 'first-page': '465', 'DOI': '10.1038/s41586-020-2196-x', 'volume': '581', 'author': 'R Wölfel', 'year': '2020', 'unstructured': 'Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of ' 'hospitalized patients with COVID-2019. Nature. 2020;581:465–9.', 'journal-title': 'Nature'}, { 'key': '517_CR22', 'doi-asserted-by': 'crossref', 'unstructured': 'Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 ' 'B.1.1.7 Lineage—United States, December 29, 2020-January 12, 2021. MMWR ' 'Morb Mortal Wkly Rep. 2021;70:95–9.', 'DOI': '10.15585/mmwr.mm7003e2'}, { 'key': '517_CR23', 'doi-asserted-by': 'publisher', 'first-page': '1284', 'DOI': '10.1016/j.cell.2020.07.012', 'volume': '182', 'author': 'Q Li', 'year': '2020', 'unstructured': 'Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 spike on ' 'viral infectivity and antigenicity. Cell. 2020;182:1284–94.', 'journal-title': 'Cell'}, { 'key': '517_CR24', 'doi-asserted-by': 'publisher', 'first-page': '142', 'DOI': '10.1038/s41586-021-03471-w', 'volume': '593', 'author': 'S Cele', 'year': '2021', 'unstructured': 'Cele S, Gazy I, Jackson L, et al. Escape of SARS-CoV-2 501Y.V2 from ' 'neutralization by convalescent plasma. Nature. 2021;593:142–6.', 'journal-title': 'Nature'}], 'container-title': 'Infectious Diseases and Therapy', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40121-021-00517-4.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s40121-021-00517-4/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40121-021-00517-4.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 11, 7]], 'date-time': '2021-11-07T14:15:07Z', 'timestamp': 1636294507000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s40121-021-00517-4'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 8, 27]]}, 'references-count': 24, 'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2021, 12]]}}, 'alternative-id': ['517'], 'URL': 'http://dx.doi.org/10.1007/s40121-021-00517-4', 'relation': {}, 'ISSN': ['2193-8229', '2193-6382'], 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'container-title-short': 'Infect Dis Ther', 'published': {'date-parts': [[2021, 8, 27]]}, 'assertion': [ { 'value': '21 May 2021', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '27 July 2021', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '27 August 2021', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit